10,022 Shares in Electromed, Inc. (NYSE:ELMD) Purchased by Barclays PLC

Barclays PLC bought a new position in shares of Electromed, Inc. (NYSE:ELMD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,022 shares of the company’s stock, valued at approximately $215,000. Barclays PLC owned approximately 0.12% of Electromed as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ELMD. State Street Corp raised its stake in Electromed by 14.5% in the third quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after buying an additional 2,800 shares during the period. Walleye Capital LLC acquired a new position in shares of Electromed in the third quarter valued at approximately $274,000. Pekin Hardy Strauss Inc. grew its position in shares of Electromed by 9.9% in the third quarter. Pekin Hardy Strauss Inc. now owns 38,185 shares of the company’s stock valued at $820,000 after purchasing an additional 3,435 shares during the last quarter. Navellier & Associates Inc. acquired a new position in shares of Electromed in the third quarter valued at approximately $368,000. Finally, Hunter Associates Investment Management LLC grew its position in shares of Electromed by 12.3% in the third quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock valued at $2,199,000 after purchasing an additional 11,250 shares during the last quarter. Institutional investors own 40.82% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 9th.

Insider Activity

In related news, Director Andrew Summers sold 17,463 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $30.09, for a total transaction of $525,461.67. Following the sale, the director now owns 189,838 shares in the company, valued at $5,712,225.42. The trade was a 8.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 14.00% of the company’s stock.

Electromed Stock Performance

Shares of ELMD opened at $33.90 on Wednesday. Electromed, Inc. has a 52-week low of $9.90 and a 52-week high of $35.07. The business’s fifty day moving average is $29.72 and its 200-day moving average is $22.46. The firm has a market cap of $286.79 million, a price-to-earnings ratio of 47.08 and a beta of 0.31.

Electromed (NYSE:ELMD) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.13. Electromed had a return on equity of 15.32% and a net margin of 11.34%. The company had revenue of $14.67 million for the quarter.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.